Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The challenge of using nanotherapy during pregnancy: Technological aspects and biomedical implications

Kelle Velasques Pereira, Renata Giacomeli, Marcelo Gomes de Gomes, Sandra Elisa Haas

ARTICLE INFO

Keywords:
Nanoparticles
Pregnancy
Drug targeting
Placenta
Fetus

ABSTRACT

During the period of pregnancy, several processes and physiological adaptations occur in the body and metabolism of a pregnant woman. These physiological adaptations in pregnant women can lead to a suppression of the immune system, favoring obstetric complications to the mother, fetus, and placental tissue. An effective pharmacological therapy for these complications is still a challenge, since some drugs during pregnancy can have deleterious and teratogenic effects. An emerging alternative to pharmacological therapy during pregnancy is drugs encapsulated in nanoparticles (NP), a recent area called nano-obstetrics. NP have the advantage of drug targeting and reduction of side effects. Then, maternal, placental, or fetal uptake can be expected, depending on the characteristics of NP. Inorganic NP, crossing the placental barrier effectively, but have several nanotoxicological effects. While organic NP appear to have a better targeting capacity and have few toxicological effects, but the studies are still scarce. Thus, in this review, we examined questions related to the use and impact of physicochemical aspects of inorganic and organic NP during pregnancy.

1. Introduction

During pregnancy in different animal species, adaptive physiological processes occur, so that another life can be generated. Because of these adaptations, pregnant women are more susceptible to infectious diseases due to suppression of the immune system [1,2]. Currently, the main infectious disease that affects pregnant women is Coronavirus 2019 (COVID-19). The etiological agent of this disease is severe acute respiratory distress syndrome-associated coronavirus-2 (SARS-CoV-2) [3]. Some studies have already shown evidence of COVID-19 intrauterine transmission [4,5]. Still, Mulvey et al. [6], demonstrated that the placenta of patients infected with COVID-19 presented thrombotic events. Also, in study of Dashraath et al. [7], they showed that mortality during pregnancy is related to the predisposition of superimposed bacterial infections, suppression of immune response and alteration of respiratory microbiome after pneumonia COVID-19 caused.

For the fetus, the most common complications are miscarriage, changes in intrauterine growth, and preterm birth [3,7]. Due to these complications, the large number of cesarean sections performed on pregnant women infected by COVID-19 is justified [8]. In view of above, an effective and safe pharmacological therapy for pregnant and fetus must develop with urgency. Preferably, with the ability to carry the drug to target/organ tissue, avoiding side effects. In this context, nanotechnology appears as a pioneering alternative to solve the aforementioned problem.

Nanotechnological innovations have helped overcome several problems in the biomedical and pharmaceutical area. Among the advances in nanotechnology, highlighted the synthesis of nanoparticles (NP) and their biomedical application. Different NP have been documented with a wide range of applications, including cancer therapy, drug administration, tissue engineering, regenerative medicine, biomolecule detection, and as antimicrobial agents [9]. Despite the use of NP for treatment of different pathologies and some metabolic disorders, studies with NP in pregnancy and impact on the fetus are still scarce. Therefore, nanoparticles can be exploited to precisely control the administration of drug during pregnancy, providing minimal risk of side effects on the fetus and mother, giving a new approach to treat pathological implications in pregnancy [10].

Given the above, the present review examines questions related to the use and impact of inorganic and organic NP during pregnancy, focusing on technological aspects associated to NP and their biological implications.

* Corresponding author. Federal University of Pampa, Campus Uruguaiana, BR 472, Km 7, 97500-970, Uruguaiana, RS, Brazil.
E-mail address: sandrahaas@unipampa.edu.br (S.E. Haas).

https://doi.org/10.1016/j.placenta.2020.08.005
Received 9 June 2020; Accepted 5 August 2020
Available online 18 August 2020
0143-4004/© 2020 Published by Elsevier Ltd.
2. Pregnancy: A recurring challenge for pharmacological therapy

Medication exposure during pregnancy can affect both mother and fetus. In fact, in clinical routine, treatment of pregnant is a recurring challenge. The opacity of studies, lack of reliable sources of information and the insecurity of pregnant towards systemic drug treatment leads to difficult clinical decision making. A careful evaluation of potential benefits and risks of a therapy and adequate control of clinical symptoms are crucial for a safe pregnancy [11]. The potential effects of drugs on fetal development depend on several factors, including gestational age, dose, dosage, route of administration and clearance of drug [12,13]. According to the Center for Disease Control and Prevention (CDC) [14] 9 out of 10 women take at least one medication during pregnancy and 70% of pregnant take at least one prescription medication. Over the past 30 years, the use of prescription drugs during the first quarter has increased by more than 60% [15].

The pregnancy induces significant changes in some physiological parameters, as the decrease in plasma proteins which increase the unbound fractions of the drug [16]. Besides that, the question of plasma proteins, pregnancy induces an increase of almost 50% in the circulating blood volume and cardiac output, leading to increased blood flow in organs. This leads to a smaller area under the curve and potential therapeutic failure, although it is compensated for to some extent by increased bioavailability during pregnancy due to prolonged intestinal transit time [17]. Other changes include increased glomerular filtration rate (increased renal clearance) and altered activity of drug-metabolizing enzymes in liver (affecting hepatic clearance) [18]. All these changes have an impact on the pharmacological results for this population.

Considering the various physiological alterations in metabolism of drugs described during pregnancy, it is clear that specific guidelines are needed for use of medications in pregnant. Despite the increase in use of medication by pregnant, previously mentioned, the amount of data available to guide decision-making is limited. The caution surrounding drug use in pregnancy became widespread after unexpected adverse events from thalidomide and diethylstilbestrol, which led to the exclusion of pregnant from clinical trials [19,20]. Scaffidi et al. [21] researched 16 clinical trial records comprising 301,538 trials and found that only 0.32% of all active trials were pregnancy drug trials. It is known that fetal drug toxicity can occur at any time during pregnancy, although the most vulnerable period for anomalies is the first trimester [22].

The great challenge for development of safe medications for use in pregnancy is to reduce or eliminate the exposure of unwanted tissues (maternal or fetal) while still providing the necessary therapeutic effect [13]. Placenta is the organ that represents the maternal-fetal interface, responsible for the transfer of oxygen, nutrients, waste and other molecules between the maternal and fetal bloodstream [23]. In humans, the placenta is of the hemochorial type and its composition consists of a maternal portion, called deciduous and a fetal portion, the chorionic plate. Fibroblasts are the origin of deciduous cells, which differentiate and form the deciduous, while the chorionic plate presents a structure of villous trees that form the placental barrier [24].

After implantation of the blastocyst, placental development begins. Initially, placental membrane is composed of four layers, the syncytiotrophoblast facing the mother, a layer of cytotrophoblastic cells, connective tissue of the villi called the stroma of the villi (containing vascular endothelium, fibroblasts and macrophages), the endothelium that lines the fetal capillaries, as well as the basement membranes of these cells [24]. During implantation and the onset of placentation, trophoblastic cells undergo extensive proliferation and differentiation. The cytotrophoblast penetrates the syncytiotrophoblast layer around the initial concept to form columns of extravillous cytotrophoblast cells. As the walls of maternal endometrial vessels are corroded, maternal blood cells reach the gaps. Arterial entrances to the lacunar system and venous exits from the gaps are established, and the branching of trophoblastic cells in the lacunar spaces results in formation of villous trees [23]. Lacunar spaces become the intervillous space where maternal blood flows between villous trees. Fetal capillaries and larger vessels carry oxygenated blood from the villi to the umbilical vein, and deoxygenated fetal blood is returned from the fetus to the placental villi via the umbilical arteries. Maternal blood in the intervillous space and fetal blood in villus capillaries are separated by a continuous layer of syncytiotrophoblast, a discontinuous layer of cytotrophoblastic cells, basal lamina, connective tissue and fetal endothelial cells [12].

The transfer between maternal and fetal circulation occurs through the endothelial-synctial membrane and depends on several factors, including membrane surface area and thickness, blood flow, hydrostatic pressure in the intervillous chamber and the difference in fetal and maternal osmotic pressure. Maternal blood, therefore, is in direct contact with the fetal chorionic tissue (trophoblast), which is the main barrier that separates the maternal circulation from fetal microvasculature. The fetus is also surrounded by a membranous sac, consisting of amnion, chorion and parietal decidua, which is quite impervious to most xenobiotics from the maternal bloodstream [12,25,26].

The placenta plays a pivotal role in fetal and maternal health, placental pathology is implicated in all common obstetric complications such as preeclampsia and intrauterine growth restriction. As a capture and exchange organ, with access to substances that circulate in maternal bloodstream, the placenta is a potential channel for the administration of fetal drugs, as well, as offering an excellent therapeutic target. However, there are currently few placental-specific therapeutics [27]. The consequences of fetal (and placental) drug exposure can be benign or involve structural or behavioral teratogenicity, or even termination of pregnancy, and are often unknown [28].

3. Nanotherapy

3.1. Nanoparticles: Characteristics, advantages and pharmaceutical considerations

Conceptually, NP are nanometer-sized (1–1000 nm) particles formed by different nanomaterials of organic or inorganic origin. In general, NP are dispersed in a colloidal system, also known as nanoformulations [28]. Among the particles of inorganic origin, metallic NP are the most used [25]. Due to its ultra-small size, they interact with DNA and enzymes, altering the pathophysiology of some diseases [29]. Still, among the particles of organic origin, the polymeric NP are highlighted, due to

![Fig. 1. Overview of review. Interaction of organic and inorganic NP with biological system during pregnancy.](image-url)
Porosity and elasticity, which can be adjusted for a specific clinical variety of materials and structures, with or without targeting binders interaction with biological system. Besides that, zeta potential is important in NP design. Because it is known that the different chemical characteristics most analyzed in NP are size, morphology, pH, charge, and/or 'stealthy' coating used in NP, it may generate a greater interaction of drug with its target tissue/organ. Depending on the polymeric coating used in NP, it may generate a greater interaction of drug with cell membrane or increase the time in blood circulation by reducing the recognition of phagocytic system.

The physicochemical characteristics of NP determined the type of interaction with biological systems (in vitro and in vivo). The physicochemical characteristics most analyzed in NP are size, morphology, pH, morphology and zeta potential. One of those characteristics that is very important is zeta potential. Because it is known that the different charges (negative or positive) present in NP determined the type of interaction with biological system. Besides that, zeta potential is directly related to NP stability in the coloidal system.

In view of these facts, the development of stable and effective NP requires a knowledge of nanomaterials physicochemical characteristics used and intended applications. In addition, the development of new therapies based on NP in pregnancy requires a thorough understanding of the mechanisms of placental transfer, nanoparticulate systems and their dependence on distinct characteristics and functionality. According to the pharmaceutical purpose, NP can be made from a wide variety of materials and structures, with or without targeting binders and/or 'stealthy' portions. The main variables that affect NP biodistribution are chemical composition, size, shape, surface chemistry, porosity and elasticity, which can be adjusted for a specific clinical application.

The biodistribution and clearance of NP in the bloodstream (pregnant or non-pregnant) is mainly dependent on the extent of renal elimination and ability to prevent sequestration by endothelial reticulum system (RES). RES removes molecules and particles from the circulation via immune cell phagocytosis and/or liver and spleen sequestration/elimination. Surface opsonization (spontaneous coating by serum proteins) is a fundamental step to facilitate this process. The natural role of opsonins is to promote the approach of bacteria and viruses by phagocytic cells, both systems with the same negative charge that inhibits the interaction between bacteria/viruses and phagocytes due to charge repulsion. After the coating of bacteria and viruses, opsonins undergo conformational rearrangements that induce biorecognition by phagocytes through specific membrane receptors. The opsonization of the xenoparticle by complement system proteins (more than 30 soluble and membrane-bound proteins) finally promotes the phagocyte removal process.

Opsonins interact with NP by van der Waals, electrostatic, ionic and hydrophobic/hydrophilic forces. Therefore, the surface characteristics of nanocarriers play a central role in this process. Hydrophobic and charged particles undergo higher opsonization when compared to hydrophilic and uncharged particles. In this way, "stealth" strategies can be employed to reduce opsonization, prevent phagocytic activation and increase tissue uptake. It is known that, long circulation nanocarriers can be obtained by coating the surface with hydrophilic polymers that prevent the opsonization process. The consequence of avoiding opsonization is the prolongation of NP permanence in the bloodstream and, with that, tissue uptake.

The role of surface loading in the transport of NP for placental barrier has been assessed in a limited number of studies with conflicting results. For example, Aengenheister et al. tested titanium dioxide NP (TiO2 NP) with different surface charges (positive and negative) in BeWo cell cultures (HPEC-A2), and there was no significant transplacental transport, but a considerable accumulation of TiO2 NP in placental tissue (showed studies of transplacental passage in Table 1).

### Table 1

| Reference | Origin/Type of NP | Model | Results |
|-----------|-------------------|-------|---------|
| [42]      | Inorganic         | Ag    | BeWo cell transcellularly transported NP was translocated to the maternal to fetal artery |
| [54]      | Organic           | PEG-PLA | Ex vivo images NP did not cause toxicity to fetus |
| [62]      | Organic           | Fluoresbrite | BeWo cell Evidence that NP are not toxic for cell culture and NP transport was observed by endocytosis and pinocytosis |
| [63]      | Organic           | Pullulan acetate | BeWo cell There was no toxicity for cell culture and NP transport was observed by endocytosis and pinocytosis |
| [64]      | Organic           | Poly (lactic-co-glycolic acid) loaded with dexamethasone | BeWo cell Nanocapsulation of the maternal-fetal transplacental permeation of dexamethasone |
| [65]      | Organic           | Polystyrene (cationic and anionic) | BeWo cell The permeability of the NP was dependent on charge, the negatively charged NP were not detected in basolateral compartment. |
| [66]      | Inorganic         | Au     | Placental perfusion There was no significant decrease in blood flow from the maternal to fetal artery |
| [67]      | Organic           | Poly-(HPMA)15-b-poly (DMAEMA)15 | Ex vivo human placenta perfusion and barrier without causing toxicity to same |

Studies available in scientific literature from the year 2012–2020. Ag (silver NP). Au (gold NP).

3.2. Drug targeting in pregnancy

Drug targeting aims to modulate and fully direct the distribution of a substance to biophase, associating appropriate system (nanocarrier). In the scientific literature, studies on the uptake or placental transfer of NP acting in drug targeting are scarce. It is known that the use of NP in pregnancy can have three different approaches: maternal, placental or fetal treatment. In this context, nanotechnology can benefit the mother, thus being a useful tool for the treatment of gestational diabetes. For example, in the treatment of preeclampsia, NP are able to release drugs directed to specific tissues without influencing uterine blood flow and fetal safety. In postpartum depression and chronic diseases that affect the central nervous system.

However, pregnancy represents a major challenge for drug targeting. NP are an alternative to overcome the problem previously exposed. Because that the NP can easily reach the placental barrier. Moreover, depending on the size, NP can cross the placental barrier. Considering that the pores of the placental barrier vary between 15 and 25 nm, a NP of up to 25 nm is able to cross the barrier via passive transport (simple diffusion). Abdelkhalil et al. developed silver-NP (Ag NP), with the ability to cross placental barrier (BeWo cell culture model) and presented a low toxicity index in fetal development. Still, the transport was described as dependent on particle size, where NP greater than 50 nm did not cross the placental barrier. In another study (in vivo), Teng et al. proved that ZnO NP with 13 nm of size crossed for placental barrier while ZnO NP with 57 nm did not have this capacity. Thus, the size of NP is directly related to your ability a drug targeting.

It is known that exposure of fetus to NP occurs mainly through the mother circulation to the fetal circulation, but this exposure may also occur through amniotic fluid. In view of above, myometrial and placental targeting allows to increase the protection to fetus with regard to the treatment of obstetric diseases. For example, in the treatment of malaria, it is necessary to obtain a limited transplacental passage, as the purpose in this case is to prevent Plasmodium from infecting erythrocytes in placental tissue. The use of a nanocarrier aimed at placenta will certainly strengthen the safety and efficiency of
potential of NP (liposomes) for drug targeting to myometrial tissue. Moreover, Li et al. [54] (such as immunoglobulin G to fetal circulation [51]. In the studies (in hypoxia situations [50], and through the transport of macromolecules -therapy [49]. NP are also able to cross the placenta and treat the fetus, as well as the advantages related to the three (targeting).

In view of above, the use of NP during pregnancy has proved to be an area of recent knowledge, with much to be understood. As mentioned in previous section, zeta potential is directly related to the interaction of NP with the placental barrier or other tissue during pregnancy [35]. When the objective is to drug targeting during pregnancy, this physicochemical characteristic of NP is very important to direct the NP (loaded with drug or not) to target tissue. It is also reiterated that depending on whether the NP is of organic or inorganic origin, they will have a different targeting due to their different physicochemical characteristics. Thus, in current review, we seek to select studies that can exemplify the effects of exposure to NP during pregnancy. Through in vivo studies (showed in Table 2) using NP, it was possible to evaluate the impact of organic and inorganic NP on placental tissue, mother and fetus as well as the advantages related to the three (targeting).

### Table 2

| Reference | Origin/Type of NP | Animal Specie | Route of administration | Results |
|-----------|------------------|---------------|-------------------------|---------|
| [39]      | Inorganic Metallic Cerium | Mice | Oral | NP abrogated the diabetes-induced embryopathy through your antioxidant effects. |
| [43]      | Inorganic Metallic ZnO | Mice | Oral | NP caused toxicity to fetus. |
| [45]      | Organic Polymeric Poly (γ-glutamic acid) and l-phenylalanine ethyl ester | Rats | Intravenous | NP prevented oxidative stress in placenta, but not in the fetus. |
| [46]      | Organic Polymeric Poly (γ-glutamic acid) and l-phenylalanine ethyl ester | Rats | Intravenous | NP caused beneficial effects dependent on sex and age on the cardiovascular function of adult offspring. |
| [48]      | Inorganic Metallic TiO₂ | Mice | Oral | NP caused a decrease in angiogenesis and activation of apoptotic pathways through caspase-3 in placental tissue. |
| [50]      | Organic Protein Zein | Mice | Oral | NP improved the delivery of compound to the maternal and fetal brains and also reduced the accumulation of fatty acids in fetal liver. |
| [55]      | Inorganic Metallic Ag coated with chitosan | Rats | Intraperitoneal | NP had a toxic effect on maternal, placenta and fetus tissues. |
| [57]      | Inorganic Metallic Ag | Rats | Inhalation | NP caused severe impacts causing fetal resorption, decreased estrogen and increased proinflammatory cytokines levels. |
| [59]      | Organic Polymeric Poly (glycidyl methacrylate) | Rats | Intravenous | There was a tissue distribution depending on the particle charge. |
| [68]      | Inorganic Metallic Au | Mice | Intravenous | There was a tissue distribution depending on the particle size. |
| [69]      | Organic Polymeric Polystyrene | Mice | Intravenous | NP with diameters up to 500 nm were absorbed by placenta and were able to cross the placental barrier. |
| [70]      | Inorganic Metallic SiO₂ | Mice | Intravenous | In clinical and histopathological evaluation, there were no changes in placental and fetal development. |
| [71]      | Inorganic Metallic TiO₂ | Mice | Subcutaneous | Maternal exposure to NP influenced the offspring central dopaminergic system. |
| [72]      | Organic Liposome Phosphatidylcholine + cholesterol | Mice | Intravenous | Prevented fetal exposure and minimized placental exposure. |
| [73]      | Inorganic Metallic Ag | Mice | Intravenous | Remarkable accumulation of silver in maternal liver and spleen, may have affected embryonic growth. |
| [74]      | Inorganic Metallic Ag | Rats | Oral | NP induced oxidative stress and apoptosis in the fetal liver. |
| [75]      | Inorganic Metallic ZnO | Chicken | Oral | NP caused abnormal expression of genes and proteins in offspring liver. |
| [76]      | Organic Polymeric Poly (ε-caprolactone) | Rats | Oral | NP did not cause toxicological effects in pregnant rats and your fetuses. |

Studies available in scientific literature from the year 2010–2020. Ce (Cerium NP), ZnO (zinc oxide NP), TiO₂ (titanium dioxide NP) Ag (silver NP), Au (gold NP), SiO₂ (silicon dioxide NP).
3.3. Implications in use of NP during pregnancy

Currently, one of the biggest challenges for use of NP during pregnancy is the nanotoxicological question. Nanotoxicological studies have to assess the impact of NP-use on the mother, fetus and placenta. In view of this problem, NP targeting is fundamental for the advancement of these studies. Thus, markers of oxidative stress, inflammatory status, DNA damage, epigenetic changes and fetal malformations must be mandatorily evaluated by nanotoxicological studies [49].

Gestational age is an important factor to be taken into account when assessing the impact of NP-use. Fennell et al. [56], evaluated the effect of using! Ag NP (administered per oral and intravenously route) on assessing the impact of NP-use. Fennell et al. [56], evaluated the effect of using Ag NP during pregnancy. We found that despite the nanotoxicological challenge, NP are promising for carrying drugs during pregnancy treating obstetric disorders related to the placental tissue, mother and fetus.

In current review, we analyzed through the scientific literature, the impact of NP-use during pregnancy. Each different nanomaterial used to form the NP will endow it with different physicochemical characteristics that directly influence the targeting and toxicity, that is, NP ability to cross the placental barrier. Despite several promising studies, nanotoxicology is a factor that prevents the application and use of NP in clinical practice. We found that the use of inorganic NP despite the advantage of crossing placental barrier, has a tendency to have deleterious effects on the placental tissue, mother and fetus. On the other hand, studies that used polymeric organic NP, seem to represent an advance for use of NP during pregnancy, due to their effectiveness in targeting and low toxicity, but they are still scarce. It can be a therapeutic alternative for complications or diseases during pregnancy. Therefore, in the future, NP will be an effective and safe alternative for use in pregnancy.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare that there are no conflicts of interest.

Acknowledgment

The authors thank a Federal University of Pampa for their financial support. This study was financed in part by the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) – Finance Code 001.

References

[1] A.C. Ewing, et al., Predictors of perinatal HIV transmission among women without prior antiretroviral therapy in a resource-limited setting: the breastfeeding, antiretrovirals and nutrition study, Pediatr. Infect. Dis. 38 (2019) 508–512.
[2] A.P. Kouris, J.S. Read, D.J. Jamieson, Pregnancy and infection, N. Engl. J. Med. 328 (2018) 2211–2218.
[3] W. Guan, et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (2020) 1708–1720.
[4] N. Yu, et al., Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study, Lancet Infect. Dis. 5 (2020) 559–564.
[5] H. Chen, et al., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, Lancet 10226 (2020) 809–815.
[6] J.J. Mulvey, et al., Analysis of complement deposition and viral RNA in placentas of COVID-19 patients, Ann. Diagn. Pathol. 46 (2020) 151530.
[7] P. Doshinath, et al., Coronavirus disease 2019 (COVID-19) pandemic and pregnancy, Am. J. Obstet. Gynecol. 222 (2020) 521–531.
[8] A.N. Della Gatta, et al., Coronavirus disease 2019 during pregnancy: a systematic review of reported cases, Am. J. Obstet. Gynecol. S0002–9378 (2020) 30438–30445.
[9] G.R. Radmardur, M.K. Smaw, Potential applications of engineered nanoparticles in medicine and biology: an update, J. Biol. Inorg. Chem. 23 (2018) 1185–1204.
[10] B. Zhang, et al., Surface-functionalized nanoparticles as efficient tools in targeted therapy of pregnancy complications, Int. J. Mol. Sci. 15 (2019) 3642.
[11] M. Riedel, B. Kuschel, Systemic drug treatment during pregnancy, Hautarzt 71 (2020) 313–323.
[12] S. Al-emaaty, et al., Placental control of drug delivery, Adv. Drug Deliv. Rev. 116 (2017) 63–72.
[13] M.D. Joshi, Drug delivery during pregnancy: how can nanomedicine be used? Ther. Deliv. 12 (2017) 1023–1025.
[14] Center for Disease Control and Prevention, USA, https://www.cdc.gov/pregnancy/meds/treatingfortwo/research.html, 2018. (Accessed 31 May 2020).
[15] A.A. Mitchell, et al., Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008, Am. J. Obstet. Gynecol. 205 (2011) 1–8.
[16] G. Pariente, et al., Pregnancy-related changes in pharmokinetics: a systematic review, PLoS Med. 13 (2016), e1002160.
[17] Y. Tanrif, J. Morado, M.F. Hebert, Pregnancy-related pharmokinetic changes, Clin. Pharmacol. Ther. 100 (2016) 53–62.
[18] M. Costantini, Physiologic and pharmokinetic changes in pregnancy, Front. Pharmacol. 5 (2014) 655.
[19] J.A. Keelam, et al., Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy, Nanomedicine 16 (2020) 2239–2247.
[20] E.A. Pinheiro, C.S. Stika, Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care, Semin. Perinatol. 44 (2020), 151221.
[21] J. Scaffidi, B.W. Mol, J.A. Keelam, The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy, Bmj 124 (2017) 132–140.
[22] S. Ito, Mother and child: medication use in pregnancy and lactation, Clin. Pharmacol. Ther. 100 (2016) 8–11.
[23] E. Malpie, S.J. Fisher, Placenta: the forgotten organ, Annu. Rev. Cell Dev. Biol. 31 (2015) 523–552.
[24] T.E. De Araujo, et al., Experimental models of maternal-fetal interface and their potential use for nanotechnology applications, Cell Biol. Int. (2019).
[25] Y. Tasrif, J. Morado, M.F. Hebert, Pregnancy-related pharmokinetic changes, Clin. Pharmacol. Ther. 100 (2016) 53–62.
[26] M. Costantini, Physiologic and pharmokinetic changes in pregnancy, Front. Pharmacol. 5 (2014) 655.
[29] V.V. Mody, et al., Introduction to metallic nanoparticles, J. Pharm. BioAllied Sci. 4 (2010) 282–289.

[30] L. Fiel, et al., Diverse deformation properties of polymeric nanoparticles and lipid-core nanocapsules, Soft Matter 7 (2011) 7240–7248.

[31] C. Wen, et al., Molecular structures and mechanisms of waterborne biodegradable polyurethane nanoparticles, Comput. Struct. Biotechnol. J. 17 (2019) 110–117.

[32] C. Chen, et al., Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug–gene co-delivery to cancer cells, Nanoscale 6 (2014) 1567–1572.

[33] S. Gutieres, et al., Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery, Int. J. Nanomed. 9 (2014) 3151–3161.

[34] L.A. Frank, et al., Chitosan as a coating material for nanoparticles intended for biomedical applications, React. Funct. Polym. 147 (2020), 104459.

[35] S. Sur, et al., Recent developments in functionalized polymer nanoparticles for efficient drug delivery system, Nano-Structures & Nano-Objects 20 (2019), 100397.

[36] Z. Zhao, et al., Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers, Adv. Drug Deliv. Rev. 143 (2019) 3–21.

[37] S. Salmaso, P. Caliceti, Stealth properties to improve therapeutic efficacy of drug nanocarriers, J. Drug. Deliv (2013), 374252, 2013.

[38] L. Fiel, et al., Diverse deformation properties of polymeric nanoparticles and lipid-core nanocapsules with different surface modifications in static and dynamic human placental transfer models, Eur. J. Pharm. and Bioph. 142 (2019) 488–497.

[39] Z. Vafaei-pour, et al., Embryo-protective effects of cerium oxide nanoparticles against gestational diabetes in mice, Iran. J. Pharm. Res. (IJPR) 17 (2018) 964–975.

[40] L. Valero, et al., Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia, Drug Discov. Today 23 (2018) 1099–1107.

[41] Z. Sarghini-Bayindir, et al., Investigations on clonazepam-loaded polymeric micelle-like nanoparticles for safe drug administration during pregnancy, Microencapsul. 35 (2018) 149–164.

[42] A. Abdelkhaliq, et al., Combination of the BeWo b30 placental transport model and the embryonic stem cell test to assess the potential developmental toxicity of silver nanoparticles, Part. Fibre Toxicol. 17 (2020) 11.

[43] C. Teng, et al., Size-dependent maternal-fetal transfer and fetal developmental toxicity of ZnO nanoparticles after oral exposures in pregnant mice, Ecotoxicol. Environ. Saf. 182 (2019) 109439.

[44] M. Saunders, Transplacental transport of nanomaterials, Nanomedicine and Nanobiotechnology 1 (2009) 671.

[45] S. Sur, et al., Recent developments in functionalized polymer nanoparticles for efficient drug delivery system, Nano-Structures & Nano-Objects 20 (2019), 100397.

[46] L. Valero, et al., Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia, Drug Discov. Today 23 (2018) 1099–1107.

[47] Z. Sarghini-Bayindir, et al., Investigations on clonazepam-loaded polymeric micelle-like nanoparticles for safe drug administration during pregnancy, Microencapsul. 35 (2018) 149–164.

[48] S. Salmaso, P. Caliceti, Stealth properties to improve therapeutic efficacy of drug nanocarriers, J. Drug. Deliv (2013), 374252, 2013.

[49] L. Aengenheister, et al., Investigating the accumulation and translocation of titanium dioxide nanoparticles oral exposure to pregnant rats and its distribution, Part. Fibre Toxicol. 16 (2019) 31.

[50] J. Zeng, et al., A nanoencapsulation suspension biomimetic of milk structure for targeting the oxytocin receptor: a potential novel treatment for obstetric complications, Int. J. Nanomed. 14 (2019) 2191–2206.

[51] B. Zhang, et al., Surface-functionalized nanoparticles as efficient tools in targeted therapy of pregnancy complications, Int. J. Mol. Sci. 20 (2019) 3642.

[52] S. Hua, B. Vaughan, In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications, Int. J. Nanomed. 14 (2019) 2191–2206.

[53] S. Hua, Synthesis and in vitro characterization of oxytocin receptor targeted PEGylated immunoliposomes for drug delivery to the uterus, J. Liposome Res. 29 (2019) 357–367.

[54] L. Li, et al., Trophoblast-targeted nanomedicine modules placental sflt 1 for preeclampsia treatment, Front. Bioeng. Biotechnol. 8 (2020) 64.

[55] K. Elsharawy, et al., Chitosan coating does not prevent the effect of the transfer of green silver nanoparticles biosynthesized by Streptomyces malachitu into fetuses via the placenta, Reprod. Biol. 20 (2020) 97–105.

[56] T.R. Fennell, et al., Disposition of intravenously or orally administered silver nanoparticles in pregnant rats and the effect on the biochemical profile in urine, J. Appl. Toxicol. 37 (2017) 530–544.

[57] L. Campagnolo, et al., Silver nanoparticles inhaled during pregnancy reach and affect the placenta and the foetus, Nanotoxicology 11 (2017) 687–698.

[58] J. Lee, et al., Titanium dioxide nanoparticles oral exposure to pregnant rats and its distribution, Part. Fibre Toxicol. 16 (2019) 31.

[59] D. Ho, et al., Maternal-placental-fetal biodistribution of multimodal polymeric nanoparticles in a pregnant rat model in mid and late gestation, Sci. Rep. 7 (2017) 2866.

[60] M.P. Pereira, et al., Cationic and anionic unloaded polymeric nanocapsules: toxicological evaluation in rats shows low toxicity, Biomed. Pharmacother. 116 (2019) 109014.

[61] M. G de Gomes, et al., Assessment of unloaded polymeric nanocapsules with different coatings in female rats: influence on toxicological and behavioral parameters, Biomed. Pharmacother. 121 (2020) 105755.

[62] L. Cartwright, et al., In vitro placental model optimization for nanoparticle transport studies, Int. J. Nanomed. 7 (2012) 497–516.

[63] H. Yang, et al., Uptake and transport of pululain acetate nanoparticles in the BeWo b30 placental barrier cell model, 2018, Int. J. Nanomed. 13 (2018) 4073–4082.

[64] H. Ali, et al., Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model, Int. J. Pharm. 454 (2013) 149–157.

[65] S.K. Kloe, et al., Translocation of positively and negatively charged polyurea nanoparticles in an in vitro placental model, Toxicol. Viro 29 (2015) 1701–1710.

[66] J.N. D’Errico, et al., Identification and quantification of gold engineered nanoparticles and impaired fluid transfer across the rat placenta via ex vivo perfusion, Biomed. Pharmacother. 117 (2019) 109148.

[67] R.L. Wilson, et al., Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium function, Placenta 93 (2020) 1–7.

[68] H. Yang, et al., Effects of nanoparticle size and gestational age on maternal biodistribution and toxicity of gold nanoparticles in pregnant mice, Toxicol. Lett. 230 (2014) 10–18.

[69] J.P. Huang, et al., Nanoparticles can cross mouse placenta and induce trophoblast apoptosis, Placenta 36 (2015) 1433–1441.

[70] A. Pietroiusti, et al., Relevance to investigate different stages of pregnancy to highlight toxic effects of nanoparticles: the example of silica, Toxicol. Appl. Pharmacol. 342 (2018) 60–68.

[71] Y. Takahashi, et al., Prenatal exposure to titanium dioxide nanoparticles increases dopamine levels in the prefrontal cortex and neostriatum of mice, J. Toxicol. Sci. 35 (2010) 749–756.

[72] J.S. Refuerzo, et al., Molecular evidence of offspring liver dysfunction after maternal exposure to zinc oxide nanoparticles, Toxicol. Appl. Pharmacol. 329 (2017) 693–705.

[73] S. Hua, et al., Surface-functionalized nanoparticles as efficient tools in targeted therapy of pregnancy complications, Int. J. Mol. Sci. 20 (2019) 3642.

[74] M. Fatemi, et al., Effects of silver nanoparticle on the developing liver of rat pups after maternal exposure, Iran. J. Pharm. Res. (IJPR) 16 (2017) 685–693.

[75] Y. Hao, et al., Molecular evidence of offspring liver dysfunction after maternal exposure to zinc oxide nanoparticles, Toxicol. Appl. Pharmacol. 329 (2017) 318–325.

[76] R. Giacomelli, et al., Curcumin-loaded poly(c-caprolactone) lipid-core nanocapsules: Evaluation of fetal and maternal toxicity, Food Chem. Toxicol. 144 (2020) 111625.